b'Foresight DiagnosticsIn turn, Chabon sees a chance to make a differ- There is a real Innovates Cancer Diagnosticsence with Foresight CLARITY, a liquid-biopsy As a sophomore at the University of Denver,platform designed to detect the presence ofpay it forward minimal residual disease (MRD) from circulating Jake Chabon, Ph.D., CEO and Chief Scientifictumor DNA (ctDNA) with unprecedented sen-Officer of Foresight Diagnostics, reached ansitivity across multiple cancers.mentality here.inflection point.This transformative technology provides an I took molecular biology, and that class blewalternative to imaging at the end of treatmentJAKE CHABON, Ph.D. CEO & CSOmy mind, Chabon recalls. I found the studyfor patients with cancer, including lymphoma.FORESIGHT DIAGNOSTICSof DNA and RNA so interesting.Chabon noted that PET scans have a consid-After graduating, Chabon spent three yearserable false positive rate. Studies have shown as a researcher at the CU Anschutz beforethat in lymphoma, approximately 50% of pursuing his Ph.D. at Stanford University. HePET-positive scans at the end of therapy do gravitated toward non-invasive blood-basednot correspond to actual relapse. Chabon cancer technology as a place of actionabilityalso noted that false-negative PET scans can to combat cancer.be equally problematic, as patients at risk of relapse may be placed under watchful waiting In2020,Chabonco-foundedForesightrather than receiving timely intervention.Diagnostics and relocated from the Bay AreaIt was very apparent to me there is an unmet to a 1,000-square-foot lab within Fitzsimonsneed, Chabon explains. Imaging has sub-Innovation Community in Aurora. Buoyed bystantial limitations, and there is a need for $86 million in funding (as of summer 2025),accurate tools to know if you are responding Foresight Diagnostics has grown from a singleto therapy to allow for precision medicine and employee (Chabon) to 110 and now occupiesmore personalized treatment strategies. a 13,000-square-foot CLIA-certified lab in Boulder, with an additional 13,000 squareForesightDiagnosticsiscontinuingtoChabon moved his company from the Bay Area to feet of office space.evolve quickly. In early 2025, the NationalColorado in 2020 and raised more than $86M by Comprehensive Cancer Network (NCCN) Clinicalmid-2025 to commercialize Foresight CLARITY.Reflecting on his return to Colorado, Chabon isPractice Guidelines in Oncology for diffuse large pleased with the pool of talent, particularly inB-cell lymphoma were updated to recommendglobal availability of the test and recently research and development, improved capitalthe inclusion of ctDNA-MRD testing. The inclu- entered into a commercial distribution part-efficiency, and a genuine willingness of fellowsion has accelerated the commercialization ofnership with QIAGEN to develop a kit-based CEOs to share ideas.Foresight CLARITY, and Foresight is planningversion of Foresight CLARITY. There is a real pay it forward mentality here,to launch the test commercially to physiciansI cant believe how much has happened in five Chabon says.and patients in early 2026. Foresight is alsoyears, and I am excited to see what the future planning for the future with an eye towardholds, Chabon says. DAY TWOAgilent Technologies, FrederickColorado State BioMed Realty,University, Fort CollinsFlatiron ParkEnveda, BoulderKBI Biopharma,Innosphere Ventures, Boulder Fort Collins2025-2026 BIOSCIENCE COLORADO 29'